NovaBay Pharmaceuticals, Inc. (NBY): Price and Financial Metrics

NovaBay Pharmaceuticals, Inc. (NBY): $0.10

0.01 (-5.85%)

POWR Rating

Component Grades

Momentum

F

Stability

F

Sentiment

Quality

C

Add NBY to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#229 of 376

in industry

NBY Price/Volume Stats

Current price $0.10 52-week high $1.95
Prev. close $0.11 52-week low $0.10
Day low $0.10 Volume 2,093,000
Day high $0.11 Avg. volume 3,658,621
50-day MA $0.15 Dividend yield N/A
200-day MA $0.40 Market Cap 683.59K

NBY Stock Price Chart Interactive Chart >

NBY POWR Grades

  • NBY scores best on the Value dimension, with a Value rank ahead of 68.77% of US stocks.
  • NBY's strongest trending metric is Growth; it's been moving down over the last 53 days.
  • NBY ranks lowest in Stability; there it ranks in the 2nd percentile.

NBY Stock Summary

  • NBY has a market capitalization of $1,175,274 -- more than approximately just 0.22% of US stocks.
  • With a price/sales ratio of 0.08, NOVABAY PHARMACEUTICALS INC has a higher such ratio than merely 1.87% of stocks in our set.
  • NOVABAY PHARMACEUTICALS INC's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is -164.73%, greater than the shareholder yield of just 2.63% of stocks in our set.
  • Stocks that are quantitatively similar to NBY, based on their financial statements, market capitalization, and price volatility, are ALGT, MRTN, BTBD, BZH, and DY.
  • NBY's SEC filings can be seen here. And to visit NOVABAY PHARMACEUTICALS INC's official web site, go to www.novabay.com.

NBY Valuation Summary

  • In comparison to the median Healthcare stock, NBY's price/earnings ratio is 100.34% lower, now standing at -0.1.
  • NBY's EV/EBIT ratio has moved up 14.9 over the prior 197 months.

Below are key valuation metrics over time for NBY.

Stock Date P/S P/B P/E EV/EBIT
NBY 2023-12-29 0.1 0.2 -0.1 -0.1
NBY 2023-12-28 0.1 0.2 -0.1 -0.1
NBY 2023-12-27 0.1 0.2 -0.1 -0.1
NBY 2023-12-26 0.1 0.2 -0.1 -0.1
NBY 2023-12-22 0.1 0.2 -0.1 -0.1
NBY 2023-12-21 0.1 0.2 -0.1 -0.1

NBY Growth Metrics

    The 5 year net income to common stockholders growth rate now stands at 34.8%.
  • The 4 year revenue growth rate now stands at -49.56%.
  • Its 4 year net cashflow from operations growth rate is now at 39.48%.
NBY's revenue has moved up $4,143,000 over the prior 15 months.

The table below shows NBY's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 12.141 -9.763 -8.952
2022-06-30 10.155 -9.542 -5.448
2022-03-31 9.243 -9.83 -5.152
2021-12-31 8.421 -9.192 -6.559
2021-09-30 7.668 -6.319 -7.42
2021-06-30 7.998 -6.221 -8.352

NBY's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • NBY has a Quality Grade of C, ranking ahead of 44.35% of graded US stocks.
  • NBY's asset turnover comes in at 0.533 -- ranking 79th of 680 Pharmaceutical Products stocks.
  • AMGN, AMRN, and UTHR are the stocks whose asset turnover ratios are most correlated with NBY.

The table below shows NBY's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.533 0.698 -7.529
2021-03-31 0.660 0.610 -9.044
2020-12-31 0.722 0.600 -7.838
2020-09-30 0.764 0.615 -6.542
2020-06-30 0.757 0.607 -3.607
2020-03-31 0.620 0.717 -1.768

NovaBay Pharmaceuticals, Inc. (NBY) Company Bio


NovaBay Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes non-antibiotic anti-infective products for the eye care market in the United States. The company was founded in 2000 and is based in Emeryville, California.


NBY Latest News Stream


Event/Time News Detail
Loading, please wait...

NBY Latest Social Stream


Loading social stream, please wait...

View Full NBY Social Stream

Latest NBY News From Around the Web

Below are the latest news stories about NOVABAY PHARMACEUTICALS INC that investors may wish to consider to help them evaluate NBY as an investment opportunity.

NovaBay Pharmaceuticals Partners with Woo University to Educate Eyecare Professionals on the Use of Amniotic Membranes

EMERYVILLE, Calif., December 06, 2023--NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces its partnership with Woo University to support the education of eyecare professionals on the use of amniotic membranes. A free webinar is being held Thursday, December 7, 2023 from 5:30-6:30 pm Pacific time, and eyecare professionals can register here. In September 2023 NovaBay commercially launched its prescription amniotic membrane product Avenova® Allograft, which is intended for use as a prote

Yahoo | December 6, 2023

NovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q3 2023 Earnings Call Transcript

NovaBay Pharmaceuticals, Inc. (AMEX:NBY) Q3 2023 Earnings Call Transcript November 9, 2023 Operator: Welcome to the NovaBay Pharmaceuticals Third Quarter 2023 Financial Results Conference Call. [Operator Instructions] As a reminder, this conference is being recorded. I would now like to turn the conference over to Ms. Jody Cain. Please go ahead, ma’am. Jody Cain: This […]

Yahoo | November 12, 2023

NovaBay Pharmaceuticals Reports Third Quarter 2023 Financial Results

EMERYVILLE, Calif., November 09, 2023--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) reports financial results for the three and nine months ended September 30, 2023 and provides a business update.

Yahoo | November 9, 2023

NovaBay Pharmaceuticals to Hold Third Quarter 2023 Conference Call on November 9, 2023

EMERYVILLE, Calif., November 02, 2023--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three and nine months ended September 30, 2023 after market close on Thursday, November 9, 2023 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.

Yahoo | November 2, 2023

NovaBay Pharmaceuticals Expands Physician Dispensed Sales Channel with New Avenova Programs

EMERYVILLE, Calif., October 11, 2023--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare, skincare and wound care products, announces the launch of two new promotional programs for ophthalmologists and optometrists who help their patients manage the symptoms of chronic dry eye with Avenova®-branded products. Through the new Avenova Loyalty Program and Avenova Affiliate Program, top Avenova eyecare professionals will have access to s

Yahoo | October 11, 2023

Read More 'NBY' Stories Here

NBY Price Returns

1-mo -35.11%
3-mo -50.98%
6-mo -77.78%
1-year -94.18%
3-year -99.68%
5-year -99.76%
YTD -50.98%
2023 -89.54%
2022 -85.21%
2021 -45.97%
2020 8.91%
2019 -16.88%

Continue Researching NBY

Want to see what other sources are saying about NovaBay Pharmaceuticals Inc's financials and stock price? Try the links below:

NovaBay Pharmaceuticals Inc (NBY) Stock Price | Nasdaq
NovaBay Pharmaceuticals Inc (NBY) Stock Quote, History and News - Yahoo Finance
NovaBay Pharmaceuticals Inc (NBY) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!